Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)
Launched by LILLE CATHOLIC UNIVERSITY · May 22, 2019
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The COHORTE-IM trial is studying patients with a condition called primary mitral insufficiency caused by a problem with the mitral valve, which is an important valve in the heart. This condition can lead to serious heart issues over time if not treated. The goal of the trial is to identify specific imaging tests (like echocardiograms and MRIs) that can help doctors understand which patients are at greater risk of complications. By knowing this, doctors can decide who might need surgery sooner or who can be monitored more closely.
To participate in the trial, individuals must be adults diagnosed with primary mitral insufficiency related to valve prolapse, confirmed through an ultrasound of the heart. Participants will be followed over time to gather information about their health and how the condition progresses. It's important to note that patients who have already had surgery on their mitral valve or have other specific heart conditions cannot take part in this study. If you're considering participation, you'll need to agree to the use of your medical records for research purposes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient with primary mitral insufficiency by prolapse (any grade) diagnosed by Trans-Thoracic Echocardiography (TTE)
- • From November 2010 to April 2019 (retrospective cohort)
- • From May 2019 to May 2024 (prospective cohort)
- • No previous surgery of the mitral valve before the first ultrasound
- • Adults
- • Patient who has been informed and not opposed to the use of his or her medical record data
- Exclusion Criteria:
- • Secondary MI
- • Primary MI without valve prolapse
- • Active endocarditis
- • Patient's refusal to participate in the study
- • Patient under guardianship or curatorship
About Lille Catholic University
Lille Catholic University, a prominent academic institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university integrates expertise from various fields to foster the development of cutting-edge medical solutions. Its commitment to ethical standards and patient-centered approaches ensures that clinical trials conducted under its auspices are rigorous, scientifically sound, and aligned with the highest standards of care. By leveraging its extensive network of researchers, healthcare professionals, and resources, Lille Catholic University plays a vital role in contributing to the enhancement of medical knowledge and the improvement of patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lomme, Nord, France
Patients applied
Trial Officials
Sylvestre Marechaux, Md, PhD
Principal Investigator
Lille Catholic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials